Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: The contribution of cytochrome P450 3A isoforms

Drug Metabolism and Disposition

Volumn 34, Issue 1, 2006, Pages 43-50

  Shayeganpour, Anooshirvan ^a   El Kadi, Ayman O S ^a   Brocks, Dion R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CELL PROTEIN; CHEMICAL COMPOUND; CYTOCHROME P450 1A1; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; CYTOCHROME P450 INHIBITOR; DEETHYLAMIODARONE; DRUG METABOLITE; ENZYME ANTIBODY; ENZYME INHIBITOR; IMMUNOLOGIC AGENT; ISOENZYME; KETOCONAZOLE; RECOMBINANT ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; IN VIVO STUDY; INHIBITION KINETICS; INTESTINE; KINETICS; LIVER; LIVER MICROSOME; MALE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; RAT; RAT STRAIN;

ADMINISTRATION, ORAL; AMIODARONE; ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HALF-LIFE; INJECTIONS, INTRAVENOUS; INTESTINES; ISOENZYMES; KETOCONAZOLE; LIVER; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 29944442940     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.006742     Document Type: Article

References (40)

1. Anastasiou-Nana M, Levis GM, and Moulopoulos S (1982) Pharmacokinetics of amiodarone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 20:524-529.
2. Barakat MM, El-Kadi AO, and du Souich P (2001) L-NAME prevents in vivo the inactivation but not the down-regulation of hepatic cytochrome P450 caused by an acute inflammatory reaction. Life Sci 69:1559-1571.
3. Benet LZ, Izumi T, Zhang Y, Silverman JA, and Wacher VJ (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Controlled Release 62:25-31.
4. Cortes A, Cascante M, Cardenas ML, and Cornish-Bowden A (2001) Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: new ways of analysing data. Biochem J 357:263-268.
5. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55:170-171.
6. Eagling VA, Tjia JF, and Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114.
7. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, and Sparreboom A (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75:448-454.
8. Fabre G, Julian B, Saint-Aubert B, Joyeux H, and Berger Y (1993) Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 21:978-985.
9. Fleishaker JC, Herman BD, Carel BJ, and Azie NE (2003) Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol 43:423-427.
10. Gharavi N and El-Kadi AO (2005) tert-Butylhydroquinone is a novel aryl hydrocarbon receptor ligand. Drug Metab Dispos 33:365-372.
11. Guengerich FP and Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391-407.
12. Hudig F, Bakker O, and Wiersinga WM (1994) Amiodarone-induced hypercholesterolemia is associated with a decrease in liver LDL receptor mRNA. FEBS Lett 341:86-90.
13. Jun AS and Brocks DR (2001) High-performance liquid chromatography assay of amiodarone in rat plasma. J Pharm Pharm Sci 4:263-268.
14. Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, and Piquette-Miller M (2004) Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos 32:20-27.
15. Kaminsky LS and Zhang QY (2003) The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 31:1520-1525.
16. Katoh M, Nakajima M, Yamazaki H, and Yokoi T (2001) Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 12:505-513.
17. Kharidia J and Eddington ND (1996) Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. Biopharm Drug Dispos 17:93-106.
18. Kodama I, Kamiya K, and Toyama J (1999) Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 84:20R-28R.
19. Kuroha M, Kayaba H, Kishimoto S, Khalil WF, Shimoda M, and Kokue E (2002) Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. J Pharm Sci 91:868-873.
20. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. Meng X, Mojaverian P, Doedee M, Lin E, Weinryb I, Chiang ST, and Kowey PR (2001) Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Am J Cardiol 87:432-435.
22. Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, and Luck JC (2000) Amiodarone: what have we learned from clinical trials? Clin Cardiol 23:73-82.
23. Paine MF, Schmiedlin-Ren P, and Watkins PB (1999) Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab Dispos 27:360-364.
24. Pollak PT, Bouillon T, and Shafer SL (2000) Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther 67:642-652.
25. Rafeiro E, Leeder RG, Daniels JM, Brien JF, and Massey TE (1990) In vitro hepatic, renal and pulmonary N-dealkylation of amiodarone. Biochem Pharmacol 39:1627-1629.
26. Riva E, Gerna M, Latini R, Giani P, Volpi A, and Maggioni A (1982) Pharmacokinetics of amiodarone in man. J Cardiovasc Pharmacol 4:264-269.
27. Seubert JM, Sinal CJ, and Bend JR (2002) Acute sodium arsenite administration induces pulmonary CYP1A1 mRNA, protein and activity in the rat. J Biochem Mol Toxicol 16:84 -95.
28. Shayeganpour A and Brocks DR (2003) Joint assay of desethylamiodarone and amiodarone by high performance liquid chromatography. J Pharm Pharm Sci 6:160.
29. Shayeganpour A, Jun AS, and Brocks DR (2005) Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 26:249-257.
30. Soyama A, Hanioka N, Saito Y, Murayama N, Ando M, Ozawa S, and Sawada J (2002) Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol Toxicol 91:174-178.
31. Trivier JM, Libersa C, Belloc C, and Lhermitte M (1993) Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report). Life Sci 52:PL91-PL96.
32. Turan VK, Mishin VM, and Thomas PE (2001) Clotrimazole is a selective and potent inhibitor of rat cytochrome P450 3A subfamily-related testosterone metabolism. Drug Metab Dispos 29:837-842.
33. Vadiei K, Troy S, Korth-Bradley J, Chiang ST, and Zimmerman JJ (1997) Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. J Clin Pharmacol 37:610-617.
34. Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2003) Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 4:423-459.
35. Wacher VJ, Silverman JA, Zhang Y, and Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330.
36. Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, and Smith BR (2004) Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos 32:172-177.
37. Wyss PA, Moor MJ, and Bickel MH (1990) Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. J Pharmacol Exp Ther 254:502-507.
38. Young RA and Mehendale HM (1986) In vitro metabolism of amiodarone by rabbit and rat liver and small intestine. Drug Metab Dispos 14:423-429.
39. Zhang QY, Wikoff J, Dunbar D, and Kaminsky L (1996) Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug Metab Dispos 24:322-328.
40. Zhao HW, Barger MW, Ma JK, Castranova V, and Ma JY (2004) Effects of exposure to diesel exhaust particles (DEP) on pulmonary metabolic activation of mutagenic agents. Mutat Res 564:103-113.